You are here: Industry Insights > tofacitinib

News List

Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia firstwordpharma
June 17, 2021
Pfizer Inc. (NYSE: PFE) and The Academic Research Organization (ARO) from the Hospital Israelita Albert Einstein today announced that the New England Journal of Medicine has published positive findings from the STOP-COVID study (NCT04469114) evaluating
FDA: Blood Clot, Death Risk Up With Higher Dose of Tofacitinib drugs
July 29, 2019
New warnings about an increased risk of thrombosis and of death among ulcerative colitis patients taking the 10 mg twice daily dose of the drug tofacitinib...
Tofacitinib-UV B light therapy combination restores skin colour in vitiligo europeanpharmaceuticalreview
April 29, 2019
Researchers have successfully applied a novel combination therapy to restore skin colour in patients with vitiligo…
Safety Trial Finds Risk of Blood Clots in Lungs and Death with Higher Dose of Tofacitinib in RA Patients; FDA to Investigate americanpharmaceuticalreview
February 27, 2019
The U.S. Food and Drug Administration (FDA) is alerting the public that a safety clinical trial found an increased risk of blood clots in the lungs and death when a 10 mg twice daily dose of tofacitinib ....
Scottish Medicines Consortium tofacitinib (Xeljanz) firstwordpharma
January 15, 2019
in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.
One Woman's Case Gives New Hope Against Disfiguring Sarcoidosis drugs
December 27, 2018
In very preliminary findings, an existing rheumatoid arthritis drug appeared to cure one woman of a rare but potentially life-threatening condition known as sarcoidosis.....
Chia Tai Tianqing Succeeded in Patent Challenge against Pfizer! Caicai
August 28, 2018
Compound Patent of Pfizer’s Blockbuster—JAK Inhibitor Tofacitinib was Fully Declared Invalid in China
EU approves Pfizer’s Xeljanz for psoriatic arthritis pharmatimes
July 05, 2018
The European Commission has approved Pfizer’s Xeljanz as a treatment for psoriatic arthritis (PsA), significantly expanding the drug’s scope.